Fundamentals MoonLake Immunotherapeutics (NASDAQ: MLTX) reported third quarter EPS of $-0.18, $0.05 better than the analyst estimate of $-0.23. Revenue for the quarter came in at $0 versus the consensus estimate of $0.
MoonLake Immunotherapeutics's stock price closed at $37.40. It is down -35.10% in the last 3 months and up 317.77% in the last 12 months.
Technical Analysist MoonLake Immunotherapeutics has a market capitalization of $2.16 billion. MLTX is trading in the middle of its 52-week range and above its 200-day simple moving average.
What does this mean? Investors are still evaluating the share price, but the stock still appears to have some upward momentum. This is a positive sign for the stock's future value.